CARTA AL DIRECTOR
Respuesta a «Seguridad y efectividad de la dapagliflozina con otro inhibidor del SGLT-2: ¿Qué decisión debemos tomar?»
Response to «Security and effectivity from the dapagliflozin with other inhibitor of the SGLT-2: What decision to take?»
Leído
7287
Vecesse ha leído el artículo
573
Total PDF
6714
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 75 | 9 | 84 |
| 2025 11 | 229 | 53 | 282 |
| 2025 10 | 187 | 25 | 212 |
| 2025 9 | 167 | 39 | 206 |
| 2025 8 | 166 | 44 | 210 |
| 2025 7 | 197 | 21 | 218 |
| 2025 6 | 199 | 18 | 217 |
| 2025 5 | 224 | 15 | 239 |
| 2025 4 | 292 | 17 | 309 |
| 2025 3 | 299 | 15 | 314 |
| 2025 2 | 218 | 8 | 226 |
| 2025 1 | 325 | 5 | 330 |
| 2024 12 | 363 | 7 | 370 |
| 2024 11 | 277 | 8 | 285 |
| 2024 10 | 233 | 8 | 241 |
| 2024 9 | 271 | 23 | 294 |
| 2024 8 | 235 | 10 | 245 |
| 2024 7 | 143 | 13 | 156 |
| 2024 6 | 175 | 17 | 192 |
| 2024 5 | 180 | 11 | 191 |
| 2024 4 | 120 | 10 | 130 |
| 2024 3 | 174 | 8 | 182 |
| 2024 2 | 139 | 7 | 146 |
| 2024 1 | 157 | 1 | 158 |
| 2023 12 | 92 | 7 | 99 |
| 2023 11 | 112 | 15 | 127 |
| 2023 10 | 151 | 11 | 162 |
| 2023 9 | 73 | 5 | 78 |
| 2023 8 | 109 | 8 | 117 |
| 2023 7 | 109 | 4 | 113 |
| 2023 6 | 110 | 11 | 121 |
| 2023 5 | 118 | 11 | 129 |
| 2023 4 | 72 | 1 | 73 |
| 2023 3 | 96 | 8 | 104 |
| 2023 2 | 77 | 6 | 83 |
| 2022 1 | 77 | 13 | 90 |
| 2022 12 | 97 | 19 | 116 |
| 2022 11 | 77 | 14 | 91 |
| 2022 10 | 62 | 13 | 75 |
| 2022 9 | 44 | 6 | 50 |
| 2022 8 | 35 | 4 | 39 |
| 2022 7 | 31 | 3 | 34 |
| 2022 6 | 27 | 6 | 33 |
| 2022 5 | 34 | 0 | 34 |
| 2022 4 | 66 | 2 | 68 |
| 2022 3 | 0 | 10 | 10 |
| 2022 2 | 0 | 4 | 4 |
Mostrar todo
